The U.S. Centers for Medicare and Medicaid Services “fully anticipate[s]” applying a Medicare Part B reimbursement rate next year of average sales price ASP plus 6% to drugs and biologicals purchased through the 340B program, CMS announced late this afternoon.
…
A U.S. House Republican task force assigned to develop proposals the party can advance if the GOP takes the majority in the November elections apparently chose not to make recommendations for the 340B program.
The Healthy Future Task Force’s affordability
…
A federal district judge was right to rule last November that drug makers Novo Nordisk and Sanofi may not tie strings to 340B pricing when providers use contract pharmacies, the federal government told a federal appeals court in Philadelphia last
…
The U.S. Department of Health and Human Services issued guidance to retail pharmacies yesterday about their “unique role … in ensuring access to comprehensive reproductive health care services”—including filling prescriptions for drugs that can end or prevent pregnancy.
Mifepristone and
…
Drug manufacturer Merck sued the federal government on Friday over the government’s May 6 letter telling the company its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal. The government warned Merck it could be
…
Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that
…
U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.
Last November, CBO estimated that drug pricing language in the House-passed Build Back
…
Hospitals enrolled in the 340B program will have to recertify their eligibility for reduced 340B drug pricing this year between Aug. 24 and Sept. 19, the U.S. Health Resources and Services Administration says.
340B covered entities must annually recertify their
…
If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary
…
Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use
…
×
*Sign up for news summaries and alerts from 340B Report